Livzon Pharma: 2025 Interim Report Published, Profit Growth Expected

Livzon Pharmaceutical Group Inc. has notified non-registered shareholders about the publication of its Interim Report 2025. English and Chinese versions of the report are available on the company's website (www.livzon.com.cn) and The Stock Exchange of Hong Kong Limited's website (www.hkexnews.hk). The company encourages shareholders to access the "Website Version" of the communication.

Non-registered holders who have difficulty with email notifications or website access can request a free printed copy of the report and all future corporate communications. Requests should be sent to the company's branch share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, or via email to 1513-ecom@vistra.com. Printed requests will apply to all future communications until a written change is received or until December 31, 2025, whichever is earlier.

For non-registered holders wishing to receive electronic corporate communications, the company advises them to contact their respective banks, brokers, custodians, nominees, or HKSCC Nominees Limited to provide an email address. Without a functional email address supplied through intermediaries, notices of publication will be sent in printed form. Shareholders with queries can contact the Branch Share Registrar's telephone hotline at (852) 2980 1333, available Monday to Friday from 9:00 a.m. to 6:00 p.m. (excluding public holidays).